日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

乳腺癌患者来源异种移植模型中帕妥珠单抗德鲁替康长期疗效的决定因素

Òdena, Andreu; Monserrat, Laia; Brasó-Maristany, Fara; García-Galea, Eduardo; Casals, Eloi; Molina, Cristina; Herencia-Ropero, Andrea; Pedretti, Flaminia; Domènech, Heura; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Esteve-Codina, Anna; Dienstmann, Rodrigo; Chandarlapaty, Sarat; Fan, Pang-Dian; Suto, Fumitaka; Oliveira, Mafalda; Prat, Aleix; Serra, Violeta

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

Omomyc 通过抑制 MYC 导致 DNA 损伤,从而克服乳腺癌中的 PARPi 耐药性。

Giuntini Fabio, González-Larreategui Íñigo, Herencia-Ropero Andrea, Casacuberta-Serra Silvia, Zacarías-Fluck Mariano F, Arnal Magdalena, Pedretti Flaminia, Martínez-Martín Sandra, Thabussot Hugo, Cano Virginia Castillo, Grueso Judit, Foradada Laia, Serrano Erika, López-Estévez Sergio, Rodriguez Olga, Guzman Marta, Rodriguez-Hernandez Adela, Brasó-Maristany Fara, Llop-Guevara Alba, Balmaña Judith, Nonell Lara, Prat Aleix, Serra Violeta, Beaulieu Marie-Eve, Whitfield Jonathan R, Massó-Vallés Daniel, Soucek Laura

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

利用替代性末端连接的转录调控来预测癌症治疗

Espín Roderic, Medina-Jover Ferran, Sigüenza-Andrade Javier, Farran-Matas Sònia, Mateo Francesca, Figueras Agnes, Sanz Rosario T, Vicent Guillermo Pablo, Shabbir Arzoo, Ruiz-Auladell Lara, Racionero-Andrés Emilio, García Irene, Baiges Alexandra, Franco-Luzón Lídia, Martínez-Tebar Adrián, Pardo-Cea Miguel Angel, Martínez-Iniesta María, Wang Xieng Chen, Cuyàs Elisabet, Menendez Javier A, Lopez-Cerda Marta, Muñoz Purificacion, Richaud Ivonne, Raya Angel, Fabregat Isabel, Villanueva Alberto, Serrat Xènia, Cerón Julián, Alemany Montserrat, Guix Inés, Herencia-Ropero Andrea, Serra Violeta, Krishnan Rehna, Mekhail Karim, Hakem Razqallah, Bruna Jordi, Barcellos-Hoff Mary Helen, Viñals Francesc, Aytes Álvaro, Pujana Miquel Angel

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

PARP1 选择性抑制剂 saruparib (AZD5305) 在患者来源的 BRCA1/2 相关癌症模型中表现出强效且持久的抗肿瘤活性

Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J Arenas, Helena Verdaguer, Fernando J Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta

Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers

了解乳腺癌异种移植模型中肿瘤生长变异性,可识别PARP抑制剂耐药性生物标志物

Voulgarelis, D; Forment, J V; Herencia Ropero, A; Polychronopoulos, D; Cohen-Setton, J; Bender, A; Serra, V; O'Connor, M J; Yates, J W T; Bulusu, K C

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

一个包含患者来源的导管原位癌小鼠导管内异种移植瘤的活体生物样本库,可识别侵袭性进展的风险因素

Stefan J Hutten ,Roebi de Bruijn ,Catrin Lutz ,Madelon Badoux ,Timo Eijkman ,Xue Chao ,Marta Ciwinska ,Michael Sheinman ,Hendrik Messal ,Andrea Herencia-Ropero ,Petra Kristel ,Lennart Mulder ,Rens van der Waal ,Joyce Sanders ,Mathilde M Almekinders ,Alba Llop-Guevara ,Helen R Davies ,Matthijs J van Haren ,Nathaniel I Martin ,Fariba Behbod ,Serena Nik-Zainal ,Violeta Serra ,Jacco van Rheenen ,Esther H Lips ,Lodewyk F A Wessels ,Colinda L G J Scheele ,Jos Jonkers

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

RAD51 灶作为预测卵巢癌铂类化疗反应的生物标志物

Amanda J Compadre # ,Lillian N van Biljon # ,Mark C Valentine ,Alba Llop-Guevara ,Emily Graham ,Bisiayo Fashemi ,Andrea Herencia-Ropero ,Emilee N Kotnik ,Isaac Cooper ,Shariska P Harrington ,Lindsay M Kuroki ,Carolyn K McCourt ,Andrea R Hagemann ,Premal H Thaker ,David G Mutch ,Matthew A Powell ,Lulu Sun ,Nima Mosammaparast ,Violeta Serra ,Peinan Zhao ,Elena Lomonosova ,Dineo Khabele ,Mary M Mullen

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

原发性乳腺癌各亚型中同源重组缺陷

Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, Andrea; Nikolaienko, Oleksii; Vintermyr, Olav K; Lillestøl, Reidun K; Minsaas, Laura; Leirvaag, Beryl; Iversen, Gjertrud T; Gilje, Bjørnar; Blix, Egil S; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Aase, Hildegunn S; Aas, Turid; Gudlaugsson, Einar G; Llop-Guevara, Alba; Serra, Violeta; Janssen, Emiel A M; Lønning, Per E; Knappskog, Stian; Eikesdal, Hans P

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

RAD51 检测在识别同源重组缺陷型肿瘤和患者分层方面的临床前体内验证

Benedetta Pellegrino #, Andrea Herencia-Ropero #, Alba Llop-Guevara, Flaminia Pedretti, Alejandro Moles-Fernández, Cristina Viaplana, Guillermo Villacampa, Marta Guzmán, Olga Rodríguez, Judit Grueso, Jose Jiménez, Enrique J Arenas, Andrea Degasperi, João M L Dias, Josep V Forment, Mark J O'Connor, O

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

鉴定出对 WEE1 或 ATR 抑制剂有反应、克服 PARP 抑制剂耐药性的乳腺癌和卵巢癌模型中分子定义的亚群。

Serra, Violeta; Wang, Anderson T; Castroviejo-Bermejo, Marta; Polanska, Urszula M; Palafox, Marta; Herencia-Ropero, Andrea; Jones, Gemma N; Lai, Zhongwu; Armenia, Joshua; Michopoulos, Filippos; Llop-Guevara, Alba; Brough, Rachel; Gulati, Aditi; Pettitt, Stephen J; Bulusu, Krishna C; Nikkilä, Jenni; Wilson, Zena; Hughes, Adina; Wijnhoven, Paul W G; Ahmed, Ambar; Bruna, Alejandra; Gris-Oliver, Albert; Guzman, Marta; Rodríguez, Olga; Grueso, Judit; Arribas, Joaquin; Cortés, Javier; Saura, Cristina; Lau, Alan; Critchlow, Susan; Dougherty, Brian; Caldas, Carlos; Mills, Gordon B; Barrett, J Carl; Forment, Josep V; Cadogan, Elaine; Lord, Christopher J; Cruz, Cristina; Balmaña, Judith; O'Connor, Mark J